Conclusions. During a ten-year period, 47 of 57 (82%) treated Group D eyes were salvaged. 47% (27/57) were salvaged with systemic and local chemotherapy alone. 20 of 57 (35%) eyes required IMRT for salvage. In our series, systemic treatment for retinoblastoma even in advanced eyes can salvage a majority of eyes, many with functional vision. Financial disclosure. Doheny core grant support: NIH Grant EY03040 and Research to Prevent Blindness 417 RBp120 THE FIRST EXPERIENCE OF RETINOBLASTOMA TREAT- MENT WITH THE USE OF SUPERSELECTIVE INTRA-AR- TERIAL CHEMOTHERAPY IN RUSSIA S.V. Saakyan1 , S.B. Yakovlev2, G.L. Kobyakov2, N.K. Serova2, A. Jarwa1 (svsaakyan@yandex.ru) 1. Moscow Helmholtz Research Institute of Eye Diseases 2. Moscow Scientific Neurosurgery Institute named after Burdenko Purpose. Evaluate the effectiveness of SSIAC in treatment of patients with multifocal retinoblastoma with vitreal seeding. Methods. 12 children of 1- 6 years of age with retinoblastoma of Stages D and E, including 9 children with binocular retinoblastomas, were managed. 10 patients underwent unsuccessful systemic chemotherapy previously. On average 3 single injections of SSIAC using a 50 mg dose of carboplatinum were conducted in each case. Results. Preservation of 8 eyes was achieved with the use of SSIAC (1 eye in a patient with monocular retinoblastoma and 7 eyes in patients with binocular retinoblastoma), resulting in 67% ocular preservation rate. Observed findings included a decrease in prominension and a development of calcifications in the main focus and the vitreal seedings. Conclusions. Conclusion: Our first experience demonstrated that SSIAC allows for ocular preservation and improves the effectiveness of therapy in children with advanced stages of retinoblastoma. Financial disclosure. None 2317 RBp121 MISSING INTRAOCULAR BLUSH IN AN ANGIOGRAPHY OF AN ADVANCED INTRAOCULAR RETINOBLASTOMA M. Holdt, S. Göricke, E. Biewald, M. Schündeln, N. Bornfeld, M. Schlamann (markus.holdt@uk-essen.de) Department of Ophthalmology, Department of Radiology, Department of Pediatric Oncology Purpose. To find out therapeutical option for a single case with advanced bilateral sporadic retinoblastoma (both eyes classified E) Methods. In a case of a 13 month old girl with bilateral sporadic retinoblastoma, both eyes were classified E (International Intraocular Retinoblastoma Classification) or Vb (Reese-Ellsworth-Classification) without light perception. All examinations including MRI showed no extraocular pathology. The more affected eye was primary enucleated without revealing histopathological risk factors. The attempt to preserve the less affected eye with superselective ophthalmic artery chemotherapy was discontinued due to not demarcated intraocular blush beside expanded exophytic tumor masses with retinal detachment. Angiography showed broad perfusion of periocular tissues like lacrimal gland or nasal mucosa and a strong anastomosis RETINOBLASTOMA Posters 54 to anterior meningeal artery. This eye was also primary enucleated without revealing histopathological risk factors. Hence no adjuvant chemotherapy, no other therapy was necessary. Results. The approach of superselective ophthalmic artery chemotherapy has limitations when intraocular blush is not definable. Conclusions. Primary enucleation with histopathological confirmed absence of risk factors still offers a therapy without any additional burden in these rare cases with clinical advice for germline mutation. Financial disclosure. None 2004 RBp122 CONSERVATIVE TREATMENT OF INTRAOCULAR RETINOBLASTOMA: A PROSPECTIVE PHASE II TRIAL FOR BILATERAL RETINOBLASTOMA WITH MACULAR OR PARAMACULAR INVOLVEMENT Christine Levy-Gabriel 1, Livia Lumbroso-Le Rouic 1, Isabelle Aerts 2, David Hajaje3, Alexia Savignoni 3, Nathalie Algret 3, François Doz 2, Laurence Desjardins 1 (christine.levy@curie.net) 1. Department of ocular oncology, Institut Curie 2. Department of oncologic pediatry, Institut Curie 3. Department of Biostatistics, Institut Curie, Paris France Purpose. Intraocular retinoblastoma treatments often associate chemotherapy and focal treatments. The protocols vary and may combine two or three drugs, and different number of cycles associated to the ocular treatments. In order to decrease the possible long term sequels of laser scars for macular or paramacular tumors, a protocol of laser reduction was initiated. Methods. Monocentric prospective phase II study including children with bilateral retinoblastoma and macular or paramacular involvement. The protocol combines 6 cycles of of 3 drugs (vincristin carboplatin and etoposide), diode laser thermotherapy sparing macula is associated from the third cycle. Results. 19 children, 23 eyes with 23 macular or paramacular tumors were included in the study (July 2004-Sept 2009). Six tumors were treated with chemotherapy alone, 2 of them presented a local recurrence. 17 tumors were treated with diode laser hyperthermy sparing macula, one of them reccured. 20 eyes were salvaged without EBRT, 1 needed EBRT, and 1 eye was enucleated Conclusions. Six cycles of of 3 drugs (vincristin carboplatin and etoposide) associated with diode laser thermotherapy sparing macula achieves good local control while probably decreasing laser macular scar. Visual function evolution will need longer follow-up. Financial disclosure. None 1857 RBp123 EXTRACTION OF RADIATION-INDUCED CATARACT IN PATIENTS WITH RETINOBLASTOMA Z. Islamov, F. Islom (dr_islamov@yahoo.com) National Center of Oncology, Uzbekistan Mercer University, United States Purpose. Analysis of Results of radiation-induced cataract extractions in patients with retinoblastoma.
Methods. From 2001 through 2010, 314 patients age 2 but
- Page 1 and 2:
XV th NH City Hotel and Tower Boliv
- Page 3 and 4: List of Congress Meetings of the In
- Page 5: Table of Contents Welcome address K
- Page 8 and 9: Keynote Lectures Lymphoma of the oc
- Page 10 and 11: The venue for the Biannual Meeting
- Page 12 and 13: Buenos Aires Downtown MAP 12 Venue
- Page 15 and 16: MORNING 8.30-10.10 Papers (Moderato
- Page 17 and 18: 50 RES 26 USING THE GLYCOLYTIC INHI
- Page 19 and 20: 2226 RES 4 NOTCH SIGNALING PROMOTES
- Page 21 and 22: a reduction in the number of living
- Page 23 and 24: array further detected copy number
- Page 25 and 26: 615 RES 21 TRB2 AND SKP2 IN THE RET
- Page 27: following treatment with 2-fluorode
- Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
- Page 32 and 33: Posters Retinoblastoma 2006 RBp100
- Page 34 and 35: 120 RBp135 MANAGEMENT OF AN ECTOPIC
- Page 36 and 37: After treatment, 10 patients lived
- Page 38 and 39: Methods. Six cycles of carboplatin
- Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
- Page 42 and 43: 4. Fluoroscopy for cannula placemen
- Page 44 and 45: Methods. A retrospective chart revi
- Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
- Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
- Page 50 and 51: months. Mean delay between beginnin
- Page 52 and 53: not associated with severity of RB.
- Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
- Page 58 and 59: (follow-up 5 years). Two years afte
- Page 61 and 62: 8.30-9.00 Poster presentations ECOp
- Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
- Page 65 and 66: Morning 8.30-9.00 Poster presentati
- Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
- Page 69 and 70: Purpose. Ocular surface squamous ne
- Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
- Page 73 and 74: of the tissues most commonly affect
- Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
- Page 77 and 78: Ocular Oncology Service, St Barthol
- Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
- Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
- Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
- Page 85 and 86: patients. The isolated involvement
- Page 87 and 88: exudative fluid from the hemangioma
- Page 89: maximum of 7 rituximab injections.
- Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
- Page 94 and 95: 8.30-9.00 Poster presentations UMp1
- Page 96 and 97: 2253 UM1 PRELIMINARY STUDY OF VASCU
- Page 98 and 99: Purpose. To determine the presence
- Page 100 and 101: gene expression profile of melanocy
- Page 102 and 103: the rarity of UM, timely completion
- Page 104 and 105:
C. Metz, T. Gkika, W. Sauerwein, N.
- Page 106 and 107:
Patients in the triamcinolone group
- Page 108 and 109:
1350 Ump101 INDUCED EXPRESSION OF P
- Page 110 and 111:
Purpose. To report the Results of R
- Page 112 and 113:
1547 Ump113 LONG-TERM OBSERVATIONS
- Page 114 and 115:
2038 Ump119 VALUE OF DOPPLER ANALYS
- Page 116:
Methods. A total of 4070 patients w
- Page 119:
First authors Naseripour, Masood No
Change language